With big bucks (and drugs) in hand, George Scangos' startup stakes out space in infectious diseases

Vir Biotechnology is going where Big Pharma has largely backed away — infectious diseases, such as HIV, hepatitis B and tuberculosis — and it's doing so with $600 million in backing from ARCH Venture Partners and others.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news